4-dimethylamino-3-p-tolyl-butan-2-one 、 碘甲烷 在
乙酸乙酯 作用下,
以
乙酸乙酯 为溶剂,
反应 1.0h,
以2.61 g of trimethyl-(3-oxo-2-p-tolyl-butyl)-ammonium iodide are obtained as an off-white solid, MS (ISP) 220.3 M+的产率得到trimethyl-(3-oxo-2-p-tolyl-butyl)-ammonium iodide
PYRIDO¬2,1-A ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS
申请人:F. Hoffmann-La Roche AG
公开号:EP1461337B1
公开(公告)日:2009-10-14
PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS
申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP1461337A1
公开(公告)日:2004-09-29
US6727261B2
申请人:——
公开号:US6727261B2
公开(公告)日:2004-04-27
US6897222B2
申请人:——
公开号:US6897222B2
公开(公告)日:2005-05-24
[EN] PYRIDO(2,1-A)ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS<br/>[FR] DERIVES DE PYRIDO(2,1-A)ISOQUINOLINE COMME INHIBITEURS DPP-IV
申请人:HOFFMANN LA ROCHE
公开号:WO2003055881A1
公开(公告)日:2003-07-10
The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.